Akers Biosciences Share Discussion Threads

[werewolfie] 07/3/2016 13:27

Hope the rise continues McM.

[wigwammer] 04/3/2016 16:03

Holding $2+ would indeed be good news. I suspect the 1-1.20 gbp spread isn't an accurate reflection of the market ie you can probably sell at 1 but not buy any volume at 1.2.Let's end the to and fro.. we're both holders, and both believe there may be something in it.Enjoy the weekend.

[mcmather] 04/3/2016 16:02

Equivalent share price here is £1.50 based on US$2.14.

[mcmather] 04/3/2016 14:59

Notwithstanding the above, looks like $2 is being tested on the nasdaq which would be a breakout of some sort.

[mcmather] 04/3/2016 14:00

ww, re "History is replete with well intentioned, inventive, energetic people who don't quite achieve what they set out to".

Notwithstanding that that comment just generally worries me a bit, what do you believe Dr Raymond F. Akers Jr., Ph.D. to have invented / patented himself, as opposed to those /the entire team who have worked for Akers Biosciences Inc?

[norbus] 03/3/2016 17:44

mcm

The same way Hilary Clinton does it too; you would need to know Chinese to check the story of approval and the order; I remember the alcohol test, the orders how they were channeled and how it ended.

[mcmather] 03/3/2016 14:07

Perhaps; but even if not how can Dr Raymond F. Akers Jr., Ph.D. look US investors in the eye and genuinely say I am trustworthy after the chronology of events detailed in post #3139? Maybe Vigo Communications can advise here?

[norbus] 03/3/2016 13:43

mcm

She must have heard of the Chinese Drug Approval Q42015

[wigwammer] 03/3/2016 11:44

Apols. Should read sub £1. A premonition!

[wigwammer] 03/3/2016 11:39

Ok mm.If you can invent an fda approved device, raise funds to support it, manufacture it, put a sales organisation around it, then that may be considered evidence that you are capable of building something of value. I'm happy that potential isn't currently reflected in the price and I could buy in sub 1p. 40k shares were traded in the US last night and the usd listing is now 50%+ above its recent trough.

[mcmather] 03/3/2016 11:04

Re has any company ever renewed any agreement of note with Akers Biosciences. It appears that the company will announce results for 2015 of just over $3m. They then have this announcement of a $2.5m 'order'; ie for nearly as much as the revenue they appear to have achieved in 2015. And how many investors here in the UK have decided to invest in Dr Raymond F. Akers Jr., Ph.D. since then? Zero.

Dr Raymond F. Akers Jr., Ph.D. has continually failed shareholders both here and, more recently, in the US.

The lack of any trades here since yesterday's announcement, in my opinion, speaks volumes of the regard that he is held in within the investor community.

Such a person should not be receiving a remuneration package of approaching $400,000, whether or not this might be the norm within industry. The most basic premise of a business is to generate a positive return. This has proved beyond Dr Raymond F. Akers Jr., Ph.D. for over a decade.

[mcmather] 03/3/2016 10:42

To summarise, the products have always had potential, there have always been decent margins and genuine contracts, recurring revenue streams (as stated, has any company EVER renewed an agreement with Akers and, if not, why not?) and, ultimately, profit, would no doubt have a significant impact on the share price.

Usual re determining the risk / reward - especially if, say, you were buying in now and hoping for 20%, 50%, 100%, 2 bagger, etc.

But this always takes me back to Dr Raymond F. Akers Jr., Ph.D. and the issue:

For any would be investor here, the first question I would ask them to consider is a very simple one; can you find / obtain a single piece of evidence, after having read the posts on here from #3055, to compel you to place your trust, as a potential shareholder, in Dr Raymond F. Akers Jr., Ph.D.?

[mcmather] 03/3/2016 10:35

ww, just going through your points;

Einstein re "doing the same thing over and over again and expecting different results"

Obviously AIM is not a "scam"; although some interesting stuff re 'orders' which are announced but which do not ultimately then happen...

However, there certainly appear instances in its history (AIM) of it being a 'gravy train' / jobs for the boys / etc.

The products have always had high margins and reference to such and a potential contract here and there and, aye, you could end up with a frothy concoction. The counter balance though being Dr Raymond F. Akers Jr., Ph.D. for the reasons posted on here.

Re the sales effort; they had this in mind for the nasdaq listing and began to put this in place in Jan 2014. The results for the fourth quarter of 2015 (ie nearly two years later) appear likely to be one of the poorest in the company's history. The company's continual failure (of shareholder value) is not unprecedented.

Re Dr Raymond F. Akers Jr., Ph.D. remuneration; previous comments / posts refer. He has overseen the continual decimation of value of long term shareholders for 13 years now. Dr Raymond F. Akers Jr., Ph.D. should be nowhere this company let alone be receiving a package of nearly $400k, shares, etc.

Re this order and he won't want this to happen again; has he learnt from 2002 and has anything changed since then?

[wigwammer] 03/3/2016 10:06

Mm - you asked me a question and then ignored the answer. What was it Einstein said?People already agree with you. The price tells you that. But the products may still have value. The hit test is fda approved. A product pitched between personal health and iot might fly. They are better funded to sell the products than ever before. His remuneration is not out of the ball park - he has invented fda approved products and the business may still find its feet. He has set a target of less than 30 days to get the novotek order moving."How many times has Dr Raymond F. Akers Jr., Ph.D. said 'X' is going to be a "home run" or "hit out of the park".. I have no idea. But looking through most of the quotes you've provided, on paper at least, zero.

[mcmather] 03/3/2016 09:47

ww, re Dr Raymond F. Akers Jr., Ph.D. role / influence here. The company bears his name, he has been the once constant since it first listed and reference is always made to his being the founder. The products have always had potential of some sort - refer any of the posts from 3055; and which refers back to 2002 - but under Dr Raymond F. Akers Jr., Ph.D. leadership this publicly listed enterprise has always failed to translate that potential in to consistent revenue streams, recurring contracts (has any company ever renewed an agreement with Akers?) and, ultimately, profit.

In my opinion, Dr Raymond F. Akers Jr., Ph.D, having overseen the continual destruction of value for long terms holders, should not be anywhere near the leadership team of this publicly listed company, should not be receiving a remuneration package of nearly $400,000, should not be receiving shares, etc, hence, the open question in the header:

25 February 2016 - Open question to Dr Raymond F. Akers Jr., Ph.D. to answer, or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences, Inc. In terms of the postings on this forum from #3055, do you consider yourself (Dr Raymond F. Akers Jr., Ph.D.) to be the most appropriate and competent individual to be leading the publicly listed enterprise that is Akers Biosciences, Inc.? If so, can you present a compelling counter case to the postings referred to?

[wigwammer] 03/3/2016 09:28

Thanks for posting algernon.Interesting comments about breathscan lync, and easy to see how market excitement may build here. It plays both on personal health and iot - areas of premium consumer and market interest.

[wigwammer] 02/3/2016 19:33

Put a CAP on it.

[norbus] 02/3/2016 18:59

ww for a punter passing just a view, you seem committed to hype the share;

[algernon2] 02/3/2016 18:13

Akers Biosciences off to a “blazing start” in 2016 says chief

[wigwammer] 02/3/2016 17:28

Mm - very happy to discuss, which is what I think we were doing before the silly distraction arrived.As a shareholder you are not just placing your faith in the ceo, but in many attributes of the stock. For what it's worth I suspect this is worthless, but then I'd hazard a 30% chance it isn't, in which case it could 10 bag. That makes it an interesting portfolio position. Some points irt your posts:First, the problem with being cynical at this level is everyone agrees with you. I'm guessing question marks about Ray Akers intentions have been doing the rounds for 10+ years... Yet it's never paid so poorly to be cynical before now, or paid so well to give him the benefit of the doubt. It trades around an all time low. Second, he has created something that may have value. It isn't easy to design and manufacture fda approved products, or get a Nasdaq listing. If it is a scam then he hasn't taken the easiest route. They don't have to sell a lot of a 90%+ gm product to get people's attention. Third, the current sales effort is unprecedented in terms of budget. Judging by the tangible equity available to them - they appear to have had a funded shot back in 2008. Funds wasted. They got it wrong. They rebuilt funds post the Nasdaq listing and are having another go. The current unprecedented effort may have an unprecedented result.Fourth, he's paid himself 300-400usd pa for 10+ years. That's probably true of many failing companies that eventually come good. Nobody bother to go back and check - no one cares at that point. Given he has invented several products, and achieved various other milestones that will have required a considerable amount of work.. it is somewhere in the stands but it isn't out of the ball park. Fifth, he's given a specific date for initiation of the Chinese order - end of this month. Not long. True - he gave similar reassurances in Dec 2014 and was made to look daft. Presumably he won't want that to happen again. Best guess is novotek weren't ready to play ball, perhaps now they are.At this level - high risk, high reward. But I think the balance is positive. Just a view. GLA